Hematological Disease
14
0
0
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
7.1%
1 terminated out of 14 trials
87.5%
+1.0% vs benchmark
14%
2 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (14)
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
AI Algorithms to Automate the TMI by VMAT Optimization Using WB-CT/MRI and Synthetic WB-CT - The AuToMI Project
Hematological Disorder in Patients With Angiodysplasia
Some Hematological Profile in Children With Chronic Kidney Disease
CMV-CTL for the Treatment of CMV Infection After HSCT
Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation
URMC Related Haplo-identical Donor BMT
XIENCE 28 Global Study
Randomized Trial:the Effect of Liquid Food on the Intake of Energy and Protein in Malignant Hematologic Patients
Assessing the Effect of Contact Isolation on Nosocomial Colonization With ESBL-EC in German Hematology/Oncology Wards
Cord Blood Transplantation for Patients With Cancer
Registry of Febrile Neutropenia and Invasive Fungal Infections
Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies
Exercise Following Autologous Peripheral Blood Stem Cell Transplantation